Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Oct. 31, 2012
Oct. 31, 2011
Revenues:    
Clinical laboratory services $ 15,177 $ 14,187
Product revenues 8,434 9,704
Royalty and license fee income 2,019 1,862
Total revenues 25,630 25,753
Operating expenses:    
Cost of clinical laboratory services 9,710 8,814
Cost of product revenues 4,184 5,137
Research and development 1,011 1,625
Selling, general, and administrative 11,415 12,385
Provision for uncollectible accounts receivable 1,594 1,286
Legal 1,700 868
Total operating expenses 29,614 30,115
Operating loss (3,984) (4,362)
Other income (expense):    
Interest (9) (2)
Other 9 9
Foreign currency gain 229 29
Loss before income taxes (3,755) (4,326)
Benefit (provision) for income taxes 64 (168)
Net loss $ (3,691) $ (4,494)
Net loss per common share:    
Basic and diluted (in Dollars per share) $ (0.09) $ (0.12)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 39,279 38,597